A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CR / complete remission rate

[Related PubMed/MEDLINE]
Total Number of Papers: 49
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CR  (>> Co-occurring Abbreviation)
Long Form:   complete remission rate
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. AML, FLAG
2019 Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China. GDP, MA, MTX, ORR, OS, PTCL
2019 The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma. ENKTL, OS, PFS, ROC
2019 Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas. DFS, ICT, LAHNSCC, OS, RCT, TPF
2019 [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center]. ASCT, MM, OS, TRM, TTP, VGPR
2018 Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study. ORR, OS
2018 Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience. AML, AML-MRC, HMA, IC, OS
2017 Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). CI, HR, LDH, OS, PFS, RP, T-PLL
2017 Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. ENKTL, OS, P-GEMOX, PFS, PR, RT
10  2017 Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. CBM, CNIs, eGFR, PR, SCr
11  2016 Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia. 5-FU, ActD, LR-GTN, MTX
12  2016 The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era. allo-SCT, ASCT, BMT, FL, OS, PFS, TRM
13  2016 [Comparison of Clinical Outcomes between P190 and P210 Trans-cripts in Adult Ph Chromosome Positive Acute Lymphoblastic Leukemia in the New Era of TKI]. HSCT, TKI
14  2016 [Expression and Prognostic Significance of H3K27 Trimethylation Protein in DLBCL]. DLBCL, H3K27me3, IHC, OR, TMA
15  2015 Combination treatment with antiEGFR monoclonal antibodies in advanced nasopharyngeal carcinoma : a meta-analysis. MFS, NPC, RCTs
16  2015 [Clinical and prognostic analysis of 30 cases of primary central nervous system lymphoma]. OS, PCNSL, PFS, SRS, WBRT
17  2015 [Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years]. AML, ORR, OS, PR, PR, RFS
18  2014 Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. AML, CI, HR, OS, RFS
19  2014 Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). PFS-6
20  2014 Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. ASCT, OS, PFS
21  2012 Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. AML, OS
22  2012 The role of decitabine for the treatment of acute myeloid leukemia. AML
23  2012 [Clinical and laboratory features of pediatric acute myeloid leukemia with inversion of chromosome 16]. AML, CBFbeta, D-FISH
24  2011 [Central nervous system lymphoma and its significance]. CNSL, IPI, PR
25  2011 [Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance]. AML, OS, RT-PCR
26  2011 [Efficacy of radiofrequency hyperthermia combined with chemotherapy in treatment of malignant pericardial effusion caused by lung cancer]. combined therapy group, RR
27  2010 [Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial]. AML, DA, TRR
28  2010 [Role of dendritic cells and their Toll-like receptor 4 in the pathogenesis of idiopathic thrombocytopenic purpura]. DC, ITP, n-CR, TLR4
29  2009 [ABVD chemotherapy scheme at day 1 and 8 for treatment of primary Hodgkin's lymphomas]. ABVD, DFS, HL
30  2008 Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. ALL, AML, HSCT
31  2006 Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea. DFS, HD, OS
32  2006 [Expression of Ki-67 and Bcl-2 in adults and children with acute lymphoblastic leukemia and its clinical significance]. ALL
33  2005 Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. BR
34  2004 Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. AML, CNS, EMI
35  2004 Treatment of atypical neurocytomas. CR-RT, IR, IR-RT
36  1998 Outcome in Hodgkin's disease: a 20-year cohort of patients. BNLI
37  1996 Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. AML
38  1996 Aggressive non-Hodgkin's lymphoma: long-term results of full dose CHOP chemotherapy, and analysis of prognostic determinant. ---
39  1994 [Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2]. ---
40  1992 Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy. ALL, AML, BMT, ID Ara-C, NHL, PR
41  1992 Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. AML, MPO, TLD
42  1991 Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL. NHL, PR
43  1989 Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage. FFP
44  1989 Treatment of childhood acute lymphoblastic leukemia with protocol TCL821: a report of Taiwan Children's Cancer Study Group. 6-MP, ADM, ALL, Ara-C, CCR, CNS, MTX, PRED, VCR
45  1986 [Clinical features and treatment results in 88 children with malignant lymphoma]. PR
46  1983 Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). ---
47  1982 Prognostic value of age and bone marrow karyotype in 78 adults with acute myelogenous leukemia. AML
48  1980 Methotrexate/L-asparaginase combination chemotherapy for patients with acute leukemia in relapse: a study of 36 children. ALL, ANLL, CML, L-ASP, MTX, TdT
49  1976 The use of the Robinson in vitro agar culture assay in adult acute leukemia. ---